Sarepta Therapeutics created an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD). DMD is an inherited disorder of progressive muscular weakness. It strikes primely boys and can rob them of a future, along with the dreams parents have for them. We created a new business strategy and campaign that focused on the power of gene therapy to rewrite the future for boys with DMD and to give them the possibility of a happy ending.
Customizable digital storybooks will help educate and sooth the anxiety of children in treatment for Duchenne muscular dystrophy (DMD).